Who Paid My Doc
Uplizna
Biological Inflammation/Rare Disease
NDC 72677-551-01
General payments
$13,565,707
Research payments
$18,667,517
Through program year 2025, $13,565,707 in general payments and $18,667,517 in research payments were reported against Uplizna (Inflammation/Rare Disease).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
4 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $7,677,410 | 21,320 |
| 2025 | Research | $16,388,763 | 89 |
| 2024 | General | $5,888,297 | 11,105 |
| 2024 | Research | $2,278,754 | 94 |
Breakdown
The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.
The top 5 of 117 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
The top 5 of 52 states; each share is of general payments naming this product in 2025 where a state was reported.
Records
32,425 general · 183 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.